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Abstract
Objective—The genetic component of alcohol use disorder is substantial, but monozygotic twin 
discordance indicates a role for nonheritable differences that could be mediated by epigenetics. 
Despite growing evidence associating epigenetics and psychiatric disorders, it is unclear how 
epigenetics, particularly DNA methylation, relate to brain function and behavior, including 
drinking behavior.
Method—The authors carried out a genome-wide analysis of DNA methylation of 18 
monozygotic twin pairs discordant for alcohol use disorder and validated differentially methylated 
regions. After validation, the authors characterized these differentially methylated regions using 
personality trait assessment and functional MRI in a sample of 499 adolescents.
Results—Hypermethylation in the 3′-protein-phosphatase-1G (PPM1G) gene locus was 
associated with alcohol use disorder. The authors found association of PPM1G hypermethylation 
with early escalation of alcohol use and increased impulsiveness. They also observed association 
of PPM1G hypermethylation with increased blood-oxygen-level-dependent response in the right 
subthalamic nucleus during an impulsiveness task.
Conclusions—Overall, the authors provide first evidence for an epigenetic marker associated 
with alcohol consumption and its underlying neurobehavioral phenotype.
Alcohol dependence and alcohol abuse are chronically relapsing disorders with a significant 
public health burden (1). Early escalation of alcohol use among adolescents is a risk factor 
for future alcohol use disorders (2) and is associated with externalizing disorders (3), which 
are characterized by high impulsiveness (4). High impulsiveness is itself a well-established 
risk factor for alcohol use disorders in adolescence (5, 6).
Twin studies indicate that the heritability of alcohol use disorder is 50%–60%, whereas 
environmental and stochastic effects account for 40%–50% of its variability (7). 
Investigation of discordant monozygotic twin pairs allows control for genetic variation, 
enabling an investigation of nonheritable effects (8). It has been suggested that nonheritable 
influences can be mediated through epigenetic mechanisms (9). Epigenetic processes are 
essential for normal cellular development and differentiation, and they allow the regulation 
of gene function through nonmutagenic mechanisms. DNA methylation, a key epigenetic 
process, is involved in various neurological and cognitive processes, such as neurogenesis 
(10), brain development (11), learning/memory (12), neurodegeneration (13), and several 
neuropsychiatric disorders (14). Differential methylation has been observed in peripheral 
blood and in brain tissue from alcohol-dependent patients, which suggests that epigenetic 
profiles may be useful as markers for alcohol use disorders (15, 16).
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Genome-wide methylation studies show that DNA methylation variability between 
monozygotic twins accounts for phenotypic discordances (17) in neuropsychiatric disorders, 
including schizophrenia (18), bipolar disorder (19), and autism spectrum disorder (20). No 
such investigation has been conducted in alcohol use disorder. While studies have reported 
associations between DNA methylation patterns and neuropsychiatric disorders, to our 
knowledge their relation to brain processes has not been investigated.
In this study, we assessed genome-wide DNA methylation in 18 monozygotic twin pairs 
from the population-based FinnTwin16 study (21) who were discordant for alcohol use 
disorder, using peripheral blood DNA to identify differentially methylated regions. We 
investigated behavioral and neuronal processes associated with the most significant 
differentially methylated region by assessing its association with alcohol-related behavior, 
personality traits, and brain activation in a functional neuroimaging epigenetics data set of 
499 adolescents from the IMAGEN study (www.imagen-europe.com) (22).
Method
FinnTwin16 Study Participants
Twin pairs were part of the FinnTwin16 study, a population-based Finnish cohort of 
monozygotic and dizygotic twins. They were studied at age 16, with subsequent surveys at 
ages 17, 18.5, and 24). Among 104 monozygotic twin pairs, 36 were discordant for alcohol 
dependence or alcohol abuse. From this group, we randomly selected 18 pairs for genome-
wide methylation analysis (Table 1; see also Table S1 in the data supplement that 
accompanies the online edition of this article). Discordant twins were selected using the 
Rutgers Alcohol Problem Index (23), administered at ages 18.5 and 24, with differences in 
DSM-III-R symptoms used as additional criteria (assessed using the Semi-Structured 
Assessment for the Genetics of Alcoholism). We focused on the Rutgers Alcohol Problem 
Index because in this age group, with a recent and short history of problems, DSM criteria 
are not sufficiently informative. Scores at ages 18 and 24 were significantly different 
between individuals with and without alcohol use disorders among the 18 twin pairs (t=
−2.552, df=16, p=0.011). At interview at age 24, blood was sampled from both twins, and 
DNA was extracted using the Gentra Autopure LS System (Gentra Systems, Minneapolis). 
Monozygosity of twin pairs was confirmed by the Paternity Testing Unit at the Finnish 
National Public Health Institute. The study protocol was approved by local ethics 
committees at Helsinki and Indiana Universities.
Genome-Wide Methylation Assay
Enrichment of unmethylated fraction of genomic DNA (gDNA) was performed by 
methylation-sensitive restriction of gDNA, amplification, and labeling prior to array 
hybridization, as previously described (24). (For more details on this and other aspects of the 
study's methodology, see the data supplement). Cy3-labeled DNA from each twin was 
hybridized with Cy5-labeled control DNA to a NimbleGen DNA Methylation 385k Array 
(Roche NimbleGen, Madison, Wisc.). The array consists of 385,000 60-mer oligonucleotide 
probes covering promoter regions and cytosine-guanine dinucleotide (CpG) islands. 
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Microarray data were normalized using GenePix Pro 6.0 (Molecular Devices, Sunnyvale, 
Calif.).
Analysis of the Array
Analysis of raw intensity data was performed using Bioconductor, an open-source software 
suite in the R statistical software environment (25). Raw intensity data were normalized 
using quantile normalization implemented in the Ringo package (26). Normalized intensities 
were log2 transformed, and the ratio between each twin pair was used for analysis. A one-
class RankProd analysis was used to identify differentially methylated probes between 
discordant twins (27). RankProd is based on nonparametric statistics derived from the rank 
product of each gene. As this procedure is similar to false-discovery-rate estimation, we 
used percentage of false positives <0.05 for selecting differentially methylated probes.
Verification of Alcohol Use Disorder-Associated Differentially Methylated Regions
Top-ranked alcohol use disorder-associated differentially methylated regions were verified in 
18 discordant twin pairs (Table 1) using bisulfite polymerase chain reaction (PCR) and the 
Sequenom EpiTYPER system (Sequenom, Hamburg). Methylation sites contained in the 
following genes were assessed: PPMG1, INS-IGF2, FMN1, SEPHS2, SLC6A3, AIM1, 
OPRL1, and PIPOX. Since we enriched samples for unmethylated fraction of the gDNA 
using methylation-sensitive restriction enzymes, assays were designed to cover areas 
containing HpaII and Hin6I cut-sites, adjacent to the 60-mer probes in the NimbleGen DNA 
Methylation. DNA was bisulfite treated using the EZ-96 DNA methylation kit (Zymo 
Research, Irvine, Calif.). Primer sequences, PCR conditions, amplicon length, and number 
of CpG sites are listed in Table S2 in the online data supplement. To detect differentially 
methylated regions, we performed paired t tests for each single CpG site detectable within 
each amplicon.
IMAGEN Study Participants
The methylation profile of the 3′-protein-phosphatase-1G (PPM1G) gene locus was 
investigated in 499 14-year-olds (Table 1) from IMAGEN, a European multicenter imaging-
genetic/epigenetic study. Participants were tested in eight assessment centers in four 
European countries. The Psytools software package (Delosis, London) was used for 
behavioral characterization. The assessment battery of questionnaires and cognitive tasks 
was self-administered both online in participants' homes and at the neuroimaging facilities. 
The study was approved by local ethics research committees at each site. Written informed 
consent was obtained from all participants and from their legal guardians. A detailed 
description of recruitment and assessment procedures as well as inclusion and exclusion 
criteria has been published previously (22).
Behavioral Characterization
Escalation of daily drinking between ages 14 and 16 was measured by calculating the 
difference in daily drinking between the two ages using the European School Survey Project 
on Alcohol and Other Drugs. Externalizing behavioral risk factors for substance abuse or 
dependence were measured with the Substance Use Risk Profile Scale (28), which assesses 
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independent risks factors, including two externalizing factors, impulsivity and sensation 
seeking (both the sum of five items). Pubertal development was determined using the 
Pubertal Development Scale (29), and a development score was obtained by calculating the 
mean of the scores on the five indicators. Data quality was controlled by context checks 
administered at the start of each task.
PPM1G Methylation Analysis
DNA was extracted from whole blood samples (∼10 mL) collected at age 14 using the 
Gentra Puregene Blood Kit (QIAGEN, Valencia, Calif.). DNA was bisulfite treated using the 
EZ-96 DNA methylation kit, and DNA methylation of PPM1G was assessed using bisulfite 
PCR and the Sequenom EpiTYPER system.
Stop Signal Task
Data on an event-related stop signal task from 393 14-year-old IMAGEN participants for 
whom complete data were available were analyzed using the contrast “stop success versus 
go success” to study neural responses to successful and unsuccessful inhibitory control (30).
Functional MRI Data Acquisition and Analysis
Structural and functional MRI (fMRI) data were acquired with 3-T scanners at eight sites 
using compatible scanning variables and the same scanning protocol at all sites. Full details 
of MRI acquisition protocols and quality checks have been described previously, including 
standardization across MRI scanners (22). Effect of MRI site was controlled for as a 
nuisance covariate in all statistical analyses. Effect of MRI site and scanner on the 
magnitude of the fMRI response has been formally evaluated previously (31). All acquired 
images were preprocessed and analyzed using SPM8 (http://www.fil.ion.ucl.ac.uk/spm) at 
NeuroSpin (Paris). We extracted regions of interest using the MarsBaR toolbox (http://
marsbar.sourceforge.net). The right inferior frontal gyrus was defined according to a human 
automated anatomical labeling atlas (32), and the right subthalamic nucleus was defined by 
the Lucerna et al. atlas (33). All regions of interest were extracted to match the stop success 
versus go success contrast t maps. The center of the resulting right inferior frontal gyrus 
region of interest was at Montreal Neurological Institute coordinates x=49, y=22, z=16, with 
a volume of 25,504 mm3. The center of the right subthalamic nucleus region of interest was 
located at coordinates x=10, y=−15, z=−5, with a volume of 1,000 mm3. Averaged beta 
values based on all voxels across time series in the regions of interest were used for all 
analyses.
PPM1G Gene Expression and Genotype Analysis
Total RNA was extracted from whole blood cells collected at age 14 using the PAXgene 
Blood RNA Kit (QIAGEN). Gene expression profiling was performed by hybridizing 
labeled cRNA on Illumina HumanHT-12 v4 Expression BeadChips (Illumina, San Diego). 
Normalized expression data of the probe mapping to PPM1G were extracted, log-
transformed, screened for outliers, and tested for association with PPM1G methylation data.
DNA was purified from whole blood samples (∼10 mL) preserved in EDTA tubes using the 
Gentra Puregene Blood Kit. Genotype information was collected at 582,982 markers using 
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the Illumina HumanHap610 Genotyping BeadChip. Genotype data from four single-
nucleotide polymorphisms (SNPs), present within 50 kb of the PPM1G CpG site analyzed 
(rs7602534, rs11675428, rs704791, and rs1260342), were tested for association with 
PPM1G methylation. Data for rs2384629, previously associated with alcohol use disorders 
(34), were imputed, and haplotypes covering the gene were calculated using Plink (http://
pngu.mgh.harvard.edu/∼purcell/plink/).
Association Analyses
The general linear model was used to determine associations among methylation of a CpG 
site present in the 3′ untranslated region (3′-UTR) of PPM1G, found differentially 
methylated in the twins discordant for alcohol use disorders, as well as PPM1G gene 
expression and genotype, quantity and frequency of drinking, escalation of daily drinking, 
impulsiveness, and stop signal task blood-oxygen-level-dependent (BOLD) responses. 
Gender, puberty, and study site were controlled for in all analyses. Handedness was 
controlled for in association analyses of BOLD activation. Corrected p values (pcorrected) 
were computed using 10,000 permutations. Partial eta-squared (η2p), a measure of effect size 
calculated after removing the contribution from other control variables, is reported for all 
associations.
Results
Genome-Wide Analysis of Differentially Methylated Genes in Monozygotic Twins 
Discordant for Alcohol Use Disorder
Genome-wide DNA methylation was first assessed by micro-array analysis in 18 
monozygotic twin pairs discordant for alcohol use disorder (Table 1) of 385,000 60-mer 
oligonucleotide probes covering both promoter regions and CpG islands. Using a 
nonparametric method and a cutoff of the estimated percentage of false positive predictions 
<0.05 and a p value <1×10−5, we identified 77 differentially methylated regions that exhibit 
an alcohol use disorder-associated differential methylation (see Table S3 in the online data 
supplement).
The majority of the 77 differentially methylated regions (68%) were hypermethylated in the 
affected twin, consistent with previous findings showing an association between DNA 
hypermethylation and alcohol use disorder (15). The identified regions were associated with 
62 genes, with 57% locatedinthe gene body, 30% in promoters, and the rest intergenic (see 
Figure S1A in the data supplement). The majority of differentially methylated regions (65%) 
were located outside of CpG-rich regions (CpG islands), with 41% of the sites located in 
shores flanking the islands, which have been implicated in gene regulation (35) (see Figure 
S1B in the data supplement).
The most significant differentially methylated regions located within genes (body and 
promoter) were divided into hypermethylated and hypomethylated regions; the top 10 
differentially methylated regions of each category are listed in Table 2. Among these 
regions, we selected those with an absolute delta (Δ) DNA methylation intensity value (the 
mean difference in DNA methylation intensity between the affected and the unaffected 
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member in each twin pair) higher than 0.5 for technical replication using mass spectrometry. 
These included differentially methylated regions in the PPMG1, INS-IGF2, FMN1, 
SEPHS2, SLC6A3, AIM1, OPRL1, and PIPOX genes, which we analyzed in the 18 
monozygotic twin pairs with a Sequenom EpiTYPER (see Table S2 in the data supplement). 
In the twins with an alcohol use disorder, we found significant increases in percent 
methylation of the CpG site in the 3′-UTR of PPM1G (p=0.005, mean Δ=2.4%) and in a 
CpG site contained in the OPRL1 probe (p=0.017, mean Δ=3.6%), confirming the findings 
from the microarray. We were unable to confirm differential DNA methylation in the other 
regions, possibly because the Sequenom assay could not interrogate the specific 
methylation-sensitive restriction enzyme cut-site driving the difference reported in the 
microarray.
Association of PPM1G Methylation, Gene Expression, and Genotype
As the PPM1G differentially methylated region showed the most significant association with 
alcohol use disorders, both in genome-wide analysis and in technical replication, we 
proceeded with a more detailed analysis and validation of PPM1G in an independent sample 
of 499 adolescents from the IMAGEN imaging-genetics study (Table 1) for whom gene 
expression and DNA methylation data were available. A linear regression analysis of 
PPM1G methylation and PPM1G gene expression revealed significant association (t=−1.93, 
p=0.027 [one-tailed]; η2p=0.007), with higher methylation levels associated with lower 
mRNA levels (see Figure S2 in the data supplement).
To rule out possible genotype effects on methylation, we performed a linear regression of 
PPM1G methylation and five SNPs, including rs2384629, which was previously reported to 
be associated with alcohol dependence (37). The other SNPs covering the PPM1G locus 
were rs7602534, rs11675428, rs704791, and rs1260342. Neither a single SNP nor a 
haplotype analysis (±50 kb of the PPM1G CpG site analyzed) yielded significant association 
with methylation of PPM1G (see Table S4 in the data supplement).
Association of PPM1G Methylation With Drinking Escalation and Trait Impulsiveness
To investigate whether the differentially methylated CpG site in PPM1G was associated with 
degree of alcohol exposure, we explored in the IMAGEN sample the association of PPM1G 
methylation and drinking measures at age 14. We found no association of PPM1G 
methylation and quantity (t=−0.45, p=0.65; η2p =0.0004) or frequency of drinking during the 
12 months prior to blood acquisition (t=−0.15, p=0.88; η2p =0.00005) or during the month 
prior to blood acquisition (t=−0.86, p=0.39; η2p=0.0017) (see Table S5 in the data 
supplement). This suggests that PPM1G hypermethylation is not caused by alcohol exposure 
at age 14. As escalation of alcohol use in adolescents is associated with increased risk for 
alcohol-related problems and alcohol use disorders (28), we explored a possible association 
of PPM1G methylation with escalation in daily use of alcohol between ages 14 and 16. We 
selected among the 499 adolescents of the IMAGEN study those who reported drinking at 
ages 14 or 16 (N=352) and found that PPM1G hypermethylation was positively associated 
with escalation of daily drinking (t=2.17, p=0.015 [one-tailed], pcorrected=0.024; η2p =0.014) 
(Figure 1A). Next, we investigated a possible association of escalation of alcohol use with 
externalizing behavioral risk factors for alcohol use disorders (36). Escalation of daily 
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drinking was associated with impulsiveness (t=2.33, p=0.020, pcorrected=0.04; η2p=0.017) 
(Figure 1B) but not with sensation seeking. Impulsiveness, in turn, was associated with 
PPM1G methylation (t=2.56, p=0.012, pcorrected=0.032; η2p =0.016; N=499) (Figure 1C), 
indicating a role of PPM1G methylation in both risky drinking and behavioral risk factors 
for alcohol use disorders in adolescents. When we controlled for impulsiveness, we lost the 
significance of the association of PPM1G methylation and escalation of daily drinking 
(p=0.065) and observed a decrease in effect size by 50% (with the η2p value decreasing from 
0.014 to 0.007). There was no association of the previously reported PPM1G SNP 
rs2384629 (34) with escalation of drinking or with trait impulsiveness (see Table S4 in the 
data supplement).
Association of PPM1G Methylation and Activation of the Subthalamic Nucleus During a 
Behavioral Inhibition Task
We examined a possible association between PPM1G methylation and brain activity during 
functional neuroimaging registration of the stop signal task, which assesses behavioral 
(motor) inhibition and is associated with alcohol use disorders (37, 38). In humans, 
voluntary inhibition of manual movements relies on a right-lateralized frontal–basal 
ganglia–thalamic pathway (39). This network includes the inferior frontal gyrus, which 
revokes planned movements through the subthalamic nucleus (40, 41) of the right 
hemisphere. We selected these regions of interest in the stop success versus go success 
contrast. In 14-year-olds (N=393) we found a positive association between PPM1G 
methylation and right subthalamic nucleus BOLD response (t=2.25, p=0.021, 
pcorrected=0.038; η2p=0.013) (Figure 2A,B) but not with right inferior frontal gyrus BOLD 
response. There was no association of the previously reported PPM1G SNP rs2384629 (34) 
with activation of the right subthalamic nucleus (see Table S4 in the data supplement).
Discussion
In a genome-wide study of DNA methylation in adult monozygotic twin pairs discordant for 
alcohol use disorders, we discovered association of hypermethylation of a differentially 
methylated region in the 3′-UTR of PPM1G with alcohol use disorder. PPM1G is a member 
of the PP2C family of serine/threonine protein phosphatases and has previously been linked 
with alcohol dependence (34). In an independent population-based sample of the IMAGEN 
cohort, we showed association of increased DNA methylation in PPM1G with early 
escalation of drinking and impulsiveness, both risk factors for future alcohol use disorders 
(5, 6). We did not find association with quantity or frequency measures in the IMAGEN 
sample at age 14; neither did we see an association of this differentially methylated region 
with amount of alcohol consumption in twins at the time of blood acquisition at age 25 (data 
not shown). Together with low levels of alcohol consumption at the time of the 
neuroimaging registration at age 14, these observations suggest that PPM1G methylation 
influences impulsiveness, which in turn may result in problematic patterns of drinking and 
behavior, as opposed to being a marker for the amount of alcohol consumption. This 
distinction is supported by previous data showing that the genetics of alcohol use disorders 
are distinct from the genetics of consumption, implicating different underlying biological 
pathways (42). We did not find association of PPM1G genotype and methylation profile, 
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suggesting that previously reported genetic associations in PPM1G (34) and the differential 
methylation of PPM1G are independent.
We speculate that differential methylation of PPM1G may be a result of unshared 
environmental factors, which we were unable to identify. Several nonfamilial risk factors 
have been associated with alcohol use disorders, especially during adolescence, including 
peer influence and affiliation with drinking peers (43, 44). It would be intriguing to 
characterize environmental factors more comprehensively to identify those associated with 
PPM1G methylation.
PPM1G methylation is associated with greater activation of the right subthalamic nucleus in 
the stop signal task when measuring stop success. This points toward an increased effort to 
carry out successful behavioral inhibition in those individuals with increased methylation of 
PPM1G. The subthalamic nucleus is a basal ganglia structure whose functions include 
transmission of inhibitory cortical signals to basal ganglia, including the striatum (46, 50, 
51). Several studies have suggested that the right subthalamic nucleus and right inferior 
frontal gyrus are correlated with response inhibition, suggesting that they form a frontal-
subcortical pathway of control inhibition (40, 45, 46). The right-lateralized subthalamic 
nucleus and inferior frontal gyrus have been used as regions of interest for response 
inhibition tasks (i.e., the stop signal task and go/no-go task) in studies reporting 
compromised impulse control in alcohol-dependent individuals (37, 38) and reduced ability 
to cancel prepotent responses (47), as well as in lesion studies (48), deep brain stimulation 
studies (49), and fMRI studies (50) of response inhibition in individuals with Parkinson's 
disease. Studies of in vivo deep brain stimulation of the sub-thalamic nucleus in Parkinson's 
patients (51) and in animal models (52) have shown a decrease in craving and regulation of 
substance preference, indicating the involvement of this brain region in neural processes that 
underlie addictive behavior.
While PPM1G methylation is independently associated with both trait impulsiveness 
(measured by the Substance Use Risk Profile Scale) and right subthalamic nucleus activation 
in the stop signal task, we found no association between trait impulsiveness and right 
subthalamic nucleus activation (data not shown). This is unsurprising, as impulsive traits do 
not necessarily correlate with behavioral indices of impulsiveness (53), which have been 
shown to load into independent principal components (54).
PPM1G is expressed in different brain areas, including in the subthalamic nucleus, where its 
gene product is thought to be involved in the dephosphorylation of metabotropic glutamate 
receptors (mGluR2/3) (57, 58), thus potentially regulating the transmission of cortical 
signals to the striatum (46, 50, 51).
Increased methylation of PPM1G is associated with reduced mRNA levels. Although these 
data were ascertained from whole blood and do not necessarily reflect gene regulation in 
specific brain areas at a particular age, they indicate that PPM1G methylation has the 
capacity to influence gene expression levels. Its localization in the 3′-UTR suggests that 
differential methylation could influence mRNA termination and stability (55). This is in line 
with evidence demonstrating the importance of intragenic methylation outside of canonical 
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CpG islands and promoter regions in regulating transcriptional activity. For example, 
intragenic methylation can act as an alternative promoter or it can regulate splicing (55). The 
PPM1G differentially methylated region is located in a shore flanking a CpG island. Similar 
localizations were observed in most differentially methylated regions identified in the 
genome-wide methylation study. Analogous to observations in cancer studies (35), this 
indicates that methylation in shores could be important in gene regulation and the 
pathophysiology of psychiatric disorders.
As methylation patterns and their regulation diverge not only across tissues and cell 
populations (56) but also between brain regions (57) and across the lifespan (58), a definitive 
validation study would have to be conducted in the subthalamic nucleus of adolescent 
postmortem brains. There are, however, no such samples in sufficient quantities to support 
an association analysis of methylation and gene expression.
In the monozygotic discordant twin pairs, there are no data available beyond age 24. Since 
both methylation patterns (58) and alcohol use disorder diagnosis (59) can change over the 
lifespan, it would be interesting to study discordant twin pairs at a later age to follow the 
trajectories of the disorder and their association with PPM1G methylation.
In conclusion, we identified a differentially methylated region in the PPM1G gene 
associated with alcohol use disorders in adults, and we provide evidence for its association 
with brain mechanisms and behaviors that underlie risk in adolescents for future alcohol-
related problems. Our data indicate that methylation of PPM1G may influence behavioral 
inhibition by altering activity of the right subthalamic nucleus, which integrates neural 
signals necessary for behavioral control.
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Figure 1. Association of PPM1G Methylation With Drinking Escalation (N=352) and Trait 
Impulsiveness (N=399) in Adolescentsa
aAs shown in panel A, PPM1G methylation is positively associated with an increase in 
amount of daily drinking (corrected p=0.024). PPM1G methylation at age 14 predicts an 
increase in daily drinking between ages 14 and 16. In panel B, an increase in amount of 
daily drinking is positively associated with impulsiveness in 16-year-old adolescents 
(corrected p=0.041). In panel C, PPM1G methylation is positively associated with 
impulsiveness (corrected p=0.032). All graphs represent data for each individual and have 
linear fit lines. In panels A and B, escalation of daily drinking is measured as the difference 
between age 14 and age 16 on an item on amount of daily drinking from the European 
School Survey Project on Alcohol and Other Drugs questionnaire (on a five-level ordinal 
scale). In panels B and C, impulsiveness is represented by a sum score of five items (on a 
five-level ordinal scale) of the Substance Use Risk Profile Scale.
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Figure 2. Association of PPM1G Methylation and Activation of the Subthalamic Nucleus During 
a Stop Signal Task in Adolescents (N=393)a
aAs shown in panel A, PPM1G methylation is positively associated with blood-oxygen-
level-dependent (BOLD) activation in the right subthalamic nucleus in 14-year-olds 
(corrected p=0.038). The graph depicts the percentage of PPM1G methylation and averaged 
beta values of activation of the right subthalamic nucleus for each individual; a linear fit line 
was added. In panel B, a coronal section shows methylation differences in activation of the 
right subthalamic nucleus (t value of activation, with a lighter color indicating a stronger 
activation) during successful inhibition, indicating an association between PPM1G 
methylation and activation of the right subthalamic nucleus (coordinates: x=10, y=−15, z=
−5).
Ruggeri et al. Page 15

























Ruggeri et al. Page 16
Table 1
Characteristics of a Sample of 18 Monozygotic Twin Pairs Discordant for Alcohol Use 
Disorder and a Sample of 499 Adolescents in a Genome-Wide Methylation Analysisa
Sample and Characteristica
Twin pairs discordant for alcohol use disorder at age 24 N %
Male 7 38.9
Alcohol dependence diagnosis 16 88.9
Alcohol abuse diagnosis 2 11.1
Mean SD
Number of DSM-III-R symptoms in the twin without a substance use diagnosis 1.6 0.26
Number of DSM-III-R symptoms in the twin with a substance use diagnosis 3.5 0.22
Adolescent sample N %
Male 222 44.5
Mean SD
Development score at age 14 (Pubertal Development Scale) (N=399) 2.88 0.56
Increase in daily amount of drinking (European School Survey Project on Alcohol and Other Drugs) (N=353) 0.83 1.06
Impulsivity at age 16 (Substance Use Risk Profile Scale) (N=399) 14.02 2.75
Sensation seeking at age 16 (Substance Use Risk Profile Scale) (N=399) 11.48 2.02
a
The twin pairs were from the FinnTwin16 study (21); the adolescent sample comprised 14-year-olds from the IMAGEN study (22). Scores on the 
Pubertal Development Scale and the European School Survey Project on Alcohol and Other Drugs are on a five-level ordinal scale. Impulsivity and 
sensation seeking scores are the sum of five questions on a five-level ordinal scale.
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Table 2
Differentially Methylated Regions in the Twin With an Alcohol Use Disorder Compared 
With the Unaffected Twin
Gene (Nimblegen Identification Number) Gene Symbol pfpa Location CpGb Context
Top hypermethylated regions (p<1×10−5)
Protein phosphatase 1G (CHR02P027457864) PPM1G <1×10−5 Body Shore
Insulin- insulin-like growth factor 2 (CHR11P002137905) INS_IGF2 <1×10−5 Body Shelf
NA (CHR05P064022468) NA 3×10−4 Intergenic Island
Nucleosome assembly protein 1-like 2 (CHRXP072351512) NAP1L2 3×10−3 Body Open sea
Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 
(CHR05P001469753)
SLC6A3 4×10−3 Body Shore
Hypothetical protein LOC149840 (CHR20P005679048) NA 4×10−3 Body Open sea
Ubiquitin-conjugating enzyme E2M pseudogene 1 (CHR16P034261914) UBE2MP1 6×10−3 Body Shore
Absent in melanoma 1 (CHR06P107065946) AIM1 7×10−3 Body Shore
NA (CHR09P069075112) NA 7×10−3 Intergenic Island
Opioid receptor-like 1 (CHR20P062188944) OPRL1 7×10−3 Body Island
Top hypomethylated regions (p<1×10−5)
Neurotrophic tyrosine kinase, receptor, type 1 (CHR01P155095309) NTRK1 >1×10−5 Body Shore
NA (CHR02P095678989) NA >1×10−5 Intergenic Shore
Formin 1 (CHR15P031274371) FMN1 >1×10−5 Body Island
Selenophosphate synthetase 2 (CHR16P030364503) SEPHS2 >1×10−5 Body Island
Myocyte enhancer factor 2D (CHR01P154736441) MEF2D 3×10−4 Body Island
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (CHR10P006245627) PFKFB3 3×10−4 Body Island
Solute carrier family 45, member 4 (CHR08P142298123) SLC45A4 4×10−4 Body Island
L-pipecolic acid oxidase (CHR17P024393350) PIPOX 4×10−4 Body Open sea
Fibroblast growth factor (acidic) intracellular binding protein 
(CHR11P065412364)
FIBP 2×10−3 Body Island
MIRLET7B host gene (nonprotein coding) (CHR22P044859950) MIRLET7BHG 2×10−3 Body Open sea
a
pfp=percentage of false positives.
b
CpG=cytosine-guanine dinucleotide.
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